ATE181559T1 - Proteinkinase - Google Patents

Proteinkinase

Info

Publication number
ATE181559T1
ATE181559T1 AT95909318T AT95909318T ATE181559T1 AT E181559 T1 ATE181559 T1 AT E181559T1 AT 95909318 T AT95909318 T AT 95909318T AT 95909318 T AT95909318 T AT 95909318T AT E181559 T1 ATE181559 T1 AT E181559T1
Authority
AT
Austria
Prior art keywords
protein kinase
disclosed
polynucleotides
wild
useful
Prior art date
Application number
AT95909318T
Other languages
English (en)
Inventor
Merl F Hoekstra
Original Assignee
Salk Inst For Biological Studi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Salk Inst For Biological Studi filed Critical Salk Inst For Biological Studi
Application granted granted Critical
Publication of ATE181559T1 publication Critical patent/ATE181559T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/963—Methods of stopping an enzyme reaction or stabilizing the test materials
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/905—Specially adapted for travel through blood circulatory system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/915—Therapeutic or pharmaceutical composition
    • Y10S977/916—Gene therapy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/924—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis using nanostructure as support of dna analysis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT95909318T 1994-01-21 1995-01-23 Proteinkinase ATE181559T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/185,359 US6060296A (en) 1991-07-03 1994-01-21 Protein kinases

Publications (1)

Publication Number Publication Date
ATE181559T1 true ATE181559T1 (de) 1999-07-15

Family

ID=22680667

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95909318T ATE181559T1 (de) 1994-01-21 1995-01-23 Proteinkinase

Country Status (7)

Country Link
US (3) US6060296A (de)
EP (1) EP0690876B1 (de)
JP (1) JP3091769B2 (de)
AT (1) ATE181559T1 (de)
CA (1) CA2158750C (de)
DE (1) DE69510410T2 (de)
WO (1) WO1995019993A1 (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2336313A1 (de) 1997-01-08 2011-06-22 Life Technologies Corporation Methoden zur Produktion von Proteinen
US6512102B1 (en) 1998-12-31 2003-01-28 Chiron Corporation Compositions and methods of diagnosis and treatment using casein kinase I
US6570003B1 (en) * 2001-01-09 2003-05-27 Lexion Genetics Incorporated Human 7TM proteins and polynucleotides encoding the same
US6746861B2 (en) * 2000-01-18 2004-06-08 Lexicon Genetics Incorporated Human kinase protein and polynucleotides encoding the same
US6841377B1 (en) 2001-06-13 2005-01-11 Lexicon Genetics Incorporated Human kinase and polynucleotides encoding the same
US6797510B1 (en) 2001-05-24 2004-09-28 Lexicon Genetics Incorporated Human kinases and polynucleotides encoding the same
US6864079B2 (en) 2001-04-06 2005-03-08 Lexicon Genetics Incorporated Human kinase and polynucleotides encoding the same
US20080050809A1 (en) * 1999-09-28 2008-02-28 Alejandro Abuin Novel human kinases and polynucleotides encoding the same
WO2001029228A1 (en) * 1999-10-18 2001-04-26 Shanghai Bio Road Gene Development Ltd. A novel polypeptide, a human casein kinase 48 and the polynucleotide encoding the polypeptide
AU2001241880A1 (en) * 2000-02-29 2001-09-12 Millennium Pharmaceuticals, Inc. 2504, 15977, and 14760, novel protein kinase family members and uses therefor
EP1261636A2 (de) * 2000-03-06 2002-12-04 Sugen, Inc. Neue humane protein-kinasen und protein-kinaseähnliche enzyme
DE10011530A1 (de) * 2000-03-13 2001-09-27 Robert Elez Hochwirksame Antisense-Oligodesoxynucleotide gegen Polio-like Kinasel
JP2004517622A (ja) * 2000-12-11 2004-06-17 レキシコン・ジェネティクス・インコーポレーテッド 新規ヒトキナーゼ及び該キナーゼをコードするポリヌクレオチド
US6448057B1 (en) * 2001-03-22 2002-09-10 Applera Corporation Isolated human casein kinase proteins, nucleic acid molecules encoding human casein kinase proteins, and uses thereof
EP1383879A4 (de) 2001-04-06 2005-05-11 Lexicon Genetics Inc Neue menschliche kinasen und diese codierende polynukleotide
US6644173B2 (en) * 2001-04-11 2003-11-11 Keuring, Incorporated Beverage filter cartridge holder
CA2446967A1 (en) * 2001-05-09 2002-11-14 Lexicon Genetics Incorporated Novel human kinases and polynucleotides encoding the same
WO2003093426A2 (en) * 2002-05-02 2003-11-13 University Of North Carolina At Chapel Hill In vitro mutagenesis, phenotyping, and gene mapping
WO2004005501A1 (en) * 2002-07-08 2004-01-15 Bayer Healthcare Ag Regulation of human casein kinase i epsilon
EP2069386A4 (de) 2006-07-21 2009-10-28 Life Technologies Corp Proteinmolekülgewichtsstandards mit hoher trennschärfe
JP5518479B2 (ja) * 2006-10-25 2014-06-11 ザ ロックフェラー ユニヴァーシティ Ａβ関連障害の処置のための方法およびその組成物
BR112016016098A2 (pt) 2014-01-09 2017-08-08 Intracellular Therapies Inc Compostos orgânicos
CA3007635A1 (en) 2015-12-07 2017-06-15 Zymergen Inc. Promoters from corynebacterium glutamicum
US11208649B2 (en) 2015-12-07 2021-12-28 Zymergen Inc. HTP genomic engineering platform
US9988624B2 (en) 2015-12-07 2018-06-05 Zymergen Inc. Microbial strain improvement by a HTP genomic engineering platform
CA3007840C (en) 2015-12-07 2020-09-15 Zymergen Inc. Microbial strain improvement by a htp genomic engineering platform
WO2018005793A1 (en) 2016-06-30 2018-01-04 Zymergen Inc. Methods for generating a glucose permease library and uses thereof
JP2019519242A (ja) 2016-06-30 2019-07-11 ザイマージェン インコーポレイテッド 細菌ヘモグロビンライブラリーを生成するための方法およびその使用
KR20200010285A (ko) 2017-05-19 2020-01-30 지머젠 인코포레이티드 증가된 nadph를 유도하는 생합성 경로의 게놈 공학
EP3635111A1 (de) 2017-06-06 2020-04-15 Zymergen, Inc. Transposonmutagenese mit hohem durchsatz
KR20200026874A (ko) 2017-06-06 2020-03-11 지머젠 인코포레이티드 대장균 개량을 위한 htp 게놈 공학 플랫폼
KR20200026878A (ko) 2017-06-06 2020-03-11 지머젠 인코포레이티드 균류 균주를 개량하기 위한 htp 게놈 공학 플랫폼
JP7350659B2 (ja) 2017-06-06 2023-09-26 ザイマージェン インコーポレイテッド Ｓａｃｃｈａｒｏｐｏｌｙｓｐｏｒａ ｓｐｉｎｏｓａの改良のためのハイスループット（ＨＴＰ）ゲノム操作プラットフォーム
US10917454B1 (en) 2019-08-01 2021-02-09 Rohde & Schwarz Gmbh & Co. Kg System and method for ATC voice quality assurance
CN113017648B (zh) * 2021-03-18 2023-03-24 内蒙古工业大学 一种脑电信号识别方法和系统

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2572092A1 (fr) * 1984-10-19 1986-04-25 Pasteur Institut Anticorps monoclonaux specifiques de la proteine kinase humaine, p 72 k, associee a l'action de l'interferon, leur obtention, leur application a la determination de la p 72 k de l'interferon
IL79255A0 (en) * 1986-06-26 1986-09-30 Hadassah Med Org Composition for metastasis prevention
AU1992392A (en) * 1991-04-30 1992-12-21 Children's Hospital Of Los Angeles Monospecific antibodies and antisera to the regulatory subunit of proline-directed protein kinase
WO1993001205A1 (en) * 1991-07-03 1993-01-21 The Salk Institute For Biological Studies Tyrosine kinase
JPH07505057A (ja) * 1993-01-21 1995-06-08 ザ サルク インスティテュート フォー バイオロジカル スタディーズ プロテインキナーゼ

Also Published As

Publication number Publication date
JP3091769B2 (ja) 2000-09-25
US5686412A (en) 1997-11-11
JPH08509504A (ja) 1996-10-08
EP0690876B1 (de) 1999-06-23
US6060296A (en) 2000-05-09
CA2158750C (en) 1999-04-13
DE69510410D1 (de) 1999-07-29
CA2158750A1 (en) 1995-07-27
WO1995019993A1 (en) 1995-07-27
EP0690876A1 (de) 1996-01-10
DE69510410T2 (de) 2000-01-20
US5756289A (en) 1998-05-26

Similar Documents

Publication Publication Date Title
DE69510410D1 (de) Proteinkinase
WO1998030694A3 (en) TUMOR NECROSIS FACTOR RECEPTORS 6α AND 6$g(b)
CA2258502A1 (en) Modified factor viii
ES2136596T3 (es) Hil-6 modificada.
DK0961831T3 (da) Humant alfa-endokin
DE69635088T2 (de) NEUTROKIN alpha
EP1082433A4 (de) Interleukine 21 und 22
ATE449850T1 (de) Mutanten von flt3-l und ihre verwendungen
EP1009814A4 (de) Kdr, ein menschlicher tyrosin kinase rezeptor
FI964833A0 (fi) Pantrofiiniset neurotroofiset tekijät
ATE487737T1 (de) 32 humane sekretierte proteine
DK0901526T3 (da) Cortistatin: neuropeptider, sammensætninger og metoder
CA2132452A1 (en) Casein kinase i-like protein kinase
CA2294566A1 (en) Ikk-.alpha. proteins, nucleic acids and methods
MX9702789A (es) Novedosas proteinas ligandos del dominio de la muerte del receptor tnf, e inhibidores de la union delos ligandos.
EP1203775A3 (de) Chemoattraktion-auslösender Faktor aus Lymphozyten und dessen Verwendung
ATE435277T1 (de) 18477, eine menschliche proteinkinase und deren verwendung
EP1443055A3 (de) Interleukine-21 und 22
DE69231710D1 (de) Tyrosinkinase
ATE103979T1 (de) Menschliches lymphotoxin.
DE69734890D1 (de) Rdgb-proteine
EE200000356A (et) DNA molekul, mis kodeerib mutantset prepro-neuropeptiidi Y, mutantne signaalpeptiid ja nende kasutamine
WO2000026243A3 (en) Transmembrane 4 proteins
WO2000039136A3 (en) Human brainiac-5
SE9604439D0 (sv) New receptor

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties